MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
0.9948
+0.0348
+3.63%
After Hours: 0.9801 -0.0147 -1.48% 18:40 02/06 EST
OPEN
0.9700
PREV CLOSE
0.9600
HIGH
1.010
LOW
0.9600
VOLUME
174.38K
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.7709
MARKET CAP
111.10M
P/E (TTM)
-3.2919
1D
5D
1M
3M
1Y
5Y
1D
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing
TipRanks · 5d ago
Cardiol Therapeutics Announces $14.85 Million Private Placement of Shares
Reuters · 5d ago
Cardiol Therapeutics kündigt Privatplatzierung über 14,85 Millionen Dollar an
Reuters · 5d ago
Weekly Report: what happened at CRDL last week (0126-0130)?
Weekly Report · 5d ago
Cardiol Therapeutics Secures $13.5 Million Bought-Deal Financing to Advance Heart Disease Programs
TipRanks · 01/26 18:27
Weekly Report: what happened at CRDL last week (0119-0123)?
Weekly Report · 01/26 10:09
Cardiol Therapeutics Raises $14.85 Million in Bought-Deal Financing to Support Late-Stage Heart Disease Programs
TipRanks · 01/23 14:43
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile · 01/23 14:16
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.